Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptococcus salivarius L12
- Development stage
- Unknown
- Lead developer
- BLIS Technologies
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Streptococcus salivarius L12 is a specific probiotic strain of the bacterium *Streptococcus salivarius*, which is a prominent member of the healthy human oral microbiota. This strain is primarily investigated and utilized for its potential to improve oral health and manage halitosis (bad breath). The mechanism of action involves the competitive exclusion of pathogenic bacteria and the production of bacteriocin-like inhibitory substances (BLIS), which are antimicrobial peptides that inhibit the growth of volatile sulfur compound (VSC)-producing bacteria such as *Porphyromonas gingivalis* and *Solobacterium moorei*. By colonizing the oral cavity and the surface of the tongue, L12 helps maintain a balanced microbial ecosystem, thereby reducing the production of malodorous gases and supporting overall periodontal health.
- Other names
- S. salivarius L12
Beyond the preview
Go deeper on Streptococcus salivarius L12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Streptococcus salivarius L12.